TNFRSF9 and autoimmune disease: Agonistic anti-CD137 mAb also reduces the incidence and severity of autoimmune diseases including experimental autoimmune encephalitis, collagen-induced arthritis, systemic lupus erythematosus, and experimental autoimmune uveoretinitis (44, 45, 47, 48).